In review of recent clinical data, expert panelists highlight novel therapeutic approaches in the setting of newly diagnosed and relapsed multiple myeloma.
EP. 1: Expert Perspectives on the Role of Traditional Versus Emerging Therapies in Multiple Myeloma
A video preview for an upcoming expert panelist discussion of recent updates in the multiple myeloma treatment landscape.
EP. 2: The Evolving Treatment Landscape of Transplant-Eligible Newly Diagnosed Multiple Myeloma
Opening discussion on the management of transplant-eligible newly diagnosed multiple myeloma, expert panelists consider the role of quadruplet therapy and transplant in this setting.
EP. 3: Should Every Patient With Newly Diagnosed MM Receive a Transplant?
In light of recent clinical trial data, key opinion leaders reflect on the appropriate selection of transplant for patients with newly diagnosed multiple myeloma.
EP. 4: Selecting The Appropriate Treatment in Transplant-Eligible Newly Diagnosed MM
A brief discussion how to select the appropriate treatment strategy in transplant-eligible newly diagnosed myeloma and whether there is a role for minimal residual disease in assessing response and treatment duration.
EP. 5: Approaching Induction Therapy for Patients With Transplant-Ineligible MM
Switching their focus to transplant-ineligible multiple myeloma, panelists review available triplet therapy regimens for induction therapy.
EP. 6: Choosing the Right Treatment for Patients With Transplant Ineligible MM
Patient and disease factors that help to select best first-line therapy in the setting of transplant-ineligible multiple myeloma.
EP. 7: Selecting Treatment Regimens for Multiple Myeloma at First Relapse
Turning to the last module, expert panelists discuss the treatment armamentarium for patients experiencing early relapse in multiple myeloma.
EP. 8: BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
Expert perspectives on recent clinical data on BCMA-targeted bispecific antibody therapy in patients with relapsed/refractory multiple myeloma.
EP. 9: Non–BCMA-Targeting Bispecific Antibodies in R/R MM
A brief review of non–BCMA-targeted bispecific antibodies under investigation in patients with relapsed/refractory multiple myeloma.
EP. 10: R/R MM: Optimizing Treatment Sequencing With Bispecific Antibodies
Before closing out their discussion on bispecific antibodies in relapsed/refractory multiple myeloma, key opinion leaders consider optimal sequencing of these agents.
EP. 11: What is the Role of CAR T-Cell Therapy in R/R MM?
Expert perspectives on the advent of CAR T-cell therapy in relapsed/refractory multiple myeloma, and how its role may integrate with bispecific antibody therapy.
EP. 12: Unmet Needs and Future Directions in Care in Multiple Myeloma
Closing out their discussion on the management of multiple myeloma, expert panelists highlight unmet needs and look toward future directions in care.
EP. 13: Recap: MRD Negativity, Frailty, and Emerging Therapies in Multiple Myeloma
An expert panel highlights novel therapeutic approaches for newly diagnosed and relapsed multiple myeloma.
2 Clarke Drive Cranbury, NJ 08512